A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

November 16, 2025

Study Completion Date

March 16, 2026

Conditions

Hepatic Insufficiency

Interventions

DRUG

MK-3543

Capsule for oral administration

Trial Locations (3)

RECRUITING

Orlando Clinical Research Center ( Site 0001), Orlando

RECRUITING

University of Miami ( Site 0003), Miami

RECRUITING

The Texas Liver Institute ( Site 0002), San Antonio

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY